Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  The Lancet

• Publication date

  1995-10-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(95)91690-3PMID 7475548
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Hemostatic alterations in cancer patients

  2005cited by this paper
• Tissue factor expression correlates with histological grade in human pancreatic cancer

  1995cited by this paper
• Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity.

  1995cited by this paper
• Myeloproliferative and metabolic causes.

  1994cited by this paper
• Cancer and thrombosis.

  1994cited by this paper
• Prevention and management of venous thrombosis.

  1994cited by this paper
• Hemostatic alterations in cancer patients.

  1992cited by this paper
• Assembly and expression of an intrinsic factor IX activator complex on the surface of cultured human endothelial cells.

  1992cited by this paper
• Cancer cell procoagulants and their implications.

  1992cited by this paper
• Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis.

  1984cited by this paper

• Optimal D-dimer value for acute deep vein thrombosis screening in the lower limb in cases with carcinomas

  2025cites this paper
• The regulation of cancer-associated thrombosis by podoplanin

  2024cites this paper
• The role of tumor-platelet interplay and micro tumor thrombi during hematogenous tumor metastasis

  2023cites this paper
• KRAS-mutant colorectal cancer cell lines cause a prothrombotic state through the upregulation of thrombin: experimental study

  2023cites this paper
• Tumor-educated platelets.

  2023cites this paper
• Tissue factor (coagulation factor III): a potential double-edge molecule to be targeted and re-targeted toward cancer

  2023cites this paper
• Coagulation Profile in Non-Haematological Malignancies

  2021cites this paper
• An Integrated Approach of the Potential Underlying Molecular Mechanistic Paradigms of SARS-CoV-2-Mediated Coagulopathy

  2021cites this paper
• Arterial Embolism in Malignancy: The Role of Surgery

  2021cites this paper
• profilaktyka i leczenie powikłań zakrzepowo-zatorowych u pacjentów z chorobą nowotworową Prevention and treatment of thromboembolic complications in patients with neoplastic disease

  2021cites this paper
• Diagnosis, Treatment, and Prevention of Cancer-Associated Thrombosis

  2020cites this paper
• Risk prediction for cancer-associated thrombosis in ambulatory patients with cancer: past, present and future.

  2020cites this paper
• Acute Leriche Syndrome in Pancreatic Adenocarcinoma: A Case Report.

  2020cites this paper
• LIM-only protein FHL2 attenuates vascular tissue factor activity, inhibits thrombus formation in mice and FHL2 genetic variation associates with human venous thrombosis

  2019cites this paper
• Shared risk factors for arterial cardiovascular diseases and venous thromboembolism

  2019cites this paper
• Platelet activation status in the diagnosis and postoperative prognosis of hepatocellular carcinoma.

  2019cites this paper
• The Role of Platelets in Tumor Growth, Metastasis, and Immune Evasion

  2019cites this paper
• [A Case Report of Luminal A Male Inflammatory Breast Cancer that Was Difficult to Treat Because of Trousseau Syndrome].

  2019cites this paper
• Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors

  2019cites this paper
• Kardiovaskulární komplikace nádorů a jejich léčby

  2018cites this paper
• Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors

  2018cites this paper
• Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.

  2018cites this paper
• Broj trombocita kao prognostički čimbenik u bolesnika s metastatskim karcinomom debelog crijeva

  2018cites this paper
• Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention

  2017cites this paper
• Venous thromboembolism and cancer

  2017cites this paper
• Tumor-Derived Tissue Factor Aberrantly Activates Complement and Facilitates Lung Tumor Progression via Recruitment of Myeloid-Derived Suppressor Cells

  2017cites this paper
• B idirectional association between arterial and venous thrombosis

  2017cites this paper
• Venous Etiologies of Acute Limb Ischemia

  2017cites this paper
• USE OF BEMIPARIN IN PATIENTS UNDERGOING MAJOR SURGERY FOR ESOPHAGEAL AND GASTRIC CANCER

  2017cites this paper
• IL-33 stimulates the release of procoagulant microvesicles from human monocytes and differentially increases tissue factor in human monocyte subsets

  2017cites this paper
• Recurrence of venous thromboembolism among adults acute leukemia patients treated at the University of Texas MD Anderson Cancer Center: Incidence and risk factors.

  2017cites this paper
• Coagulation factor levels in relation to venous thrombosis and cancer: Results from the MEGA study

  2016cites this paper
• Acute nontraumatic splenic infarctions at a tertiary-care center: causes and predisposing factors in 123 patients

  2016cites this paper
• PROGRESSION OF CANCER : FOCUS ON METASTASIS WITH DIFFERENT ASPECTS

  2016cites this paper
• Cancer and venous thromboembolism

  2015cites this paper
• Prevention of venous thromboembolism in cancer patients

  2015cites this paper
• Rôle de la Protéine C, un anticoagulant naturel, dans l’association thrombose et cancer

  2015cites this paper
• Венозные тромбозы у детей со злокачественными новообразованиями (обзор литературы)

  2015cites this paper
• From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications.

  2015cites this paper
• Тромбогеморрагические осложнения в онкохирургии

  2015cites this paper
• PAR 1 Receptor / Protein Interactions 1 From Multiple PAR 1 Receptor / Protein Interactions to their Multiple Therapeutic Implications

  2015cites this paper
• The Expression of the Thrombin Receptors PAR-3 and PAR-4 is Downregulated in Pancreatic Cancer Cell Lines

  2014cites this paper
• Venous Thromboembolism among Cancer Patients:A Review

  2014cites this paper
• Cancer-Associated Thrombosis: An Overview

  2014cites this paper
• 造血器悪性腫瘍に合併する血栓症，DICの予防・治療

  2014cites this paper
• Study of the thrombogenicity induced by the cytotoxic treatment of malignant disease

  2014cites this paper
• Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.

  2014cites this paper
• Overview of Extracellular Vesicles in Health and Disease

  2014cites this paper
• Statins, aspirin and risk of venous thromboembolic events in breast cancer patients

  2014cites this paper
• cells: implications for tumor progression and angiogenesis Oncogenic events regulate tissue factor expression in colorectal cancer

  2013cites this paper
• “Tissue factor expressed by microparticles is associated with mortality but not with thrombosis in cancer patients.” Reply to a comment by Geddings and Mackman

  2013cites this paper
• Tumor Growth and Metastasis

  2013cites this paper
• Venous thromboembolism and cancer.

  2013cites this paper
• Thromboembolic disease in cancer patients

  2013cites this paper
• Tumour and microparticle tissue factor expression and cancer thrombosis.

  2013cites this paper
• Tromboemboli Vena pada Kanker

  2013cites this paper
• Diagnosis and management of people with venous thromboembolism and advanced cancer: how do doctors decide? a qualitative study

  2012cites this paper
• Classification, Functions, and Clinical Relevance of Extracellular Vesicles

  2012cites this paper
• Anticoagulants in cancer

  2012cites this paper
• Endothelial cell activation markers in cancer.

  2012cites this paper
• Management of cancer-associated thrombosis in people with advanced disease

  2012cites this paper
• Coagulation activation and microparticle-associated coagulant activity in cancer patients

  2012cites this paper
• Effect of tissue factor on invasion inhibition and apoptosis inducing effect of oxaliplatin in human gastric cancer cell.

  2012cites this paper
• Venous thromboembolism in cancer patients

  2012cites this paper
• Thrombin stimulates integrin β1-dependent adhesion of human pancreatic cancer cells to vitronectin through protease-activated receptor (PAR)-1.

  2012cites this paper
• Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology.

  2012cites this paper
• Compositional Determinants of the Pharmacological Actions of Heparins

  2012cites this paper
• Circulating microparticles in patients with benign and malignant ovarian tumors.

  2012cites this paper
• Cyclooxygenase-2-Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a SIRT1-Dependent-Manner Running title: Barbieri et al.; Prostacyclin regulates thrombosis via SIRT1

  2012cites this paper
• Cyclooxygenase-2–Derived Prostacyclin Regulates Arterial Thrombus Formation by Suppressing Tissue Factor in a Sirtuin-1–Dependent-Manner

  2012cites this paper
• Tissue Factor Counteracts Effects of Oxaliplatin in Human Gastric Cancer Cells

  2012cites this paper
• Arterial and Venous Thrombosis in Cancer Patients

  2011cites this paper
• Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis

  2011cites this paper
• Venous thromboembolism in patients with pancreatic cancer: implications of circulating tissue factor

  2011cites this paper
• The association with age, human tissue kallikreins 6 and 10 and hemostatic markers for survival outcome from epithelial ovarian cancer

  2011cites this paper
• Contribution of platelets to tumour metastasis

  2011cites this paper
• Peripheral arterial ischemic events in cancer patients

  2011cites this paper
• Gerinnung bei schwerer Sepsis unter besonderer Berücksichtigung der Monozyten

  2010cites this paper
• Thrombin-activated receptors: promising targets for cancer therapy?

  2010cites this paper
• The perioperative management of patients with gynaecological cancer undergoing major surgery: A debated clinical challenge.

  2010cites this paper
• Why do cells release vesicles?

  2010cites this paper
• Erythropoiesis stimulating agents, thrombosis and cancer.

  2010cites this paper
• Microparticles and Exosomes in Gynecologic Neoplasias

  2010cites this paper
• ATVB In Focus Tissue Factor: Past, Present, and Future

  2010cites this paper
• Tissue Factor : Past , Present , and Future Series

  2010cites this paper
• Microparticles and exosomes in gynecologic neoplasias.

  2010cites this paper
• Epidemiology and pathophysiology of cancer-associated thrombosis

  2010cites this paper
• Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma

  2010cites this paper
• Heparin and low-molecular weight heparins in thrombosis and beyond.

  2010cites this paper
• Angiogenesis and Lymphangiogenesis in Colon Cancer Metastasis

  2010cites this paper
• Elevated numbers and altered subsets of procoagulant microparticles in breast cancer patients using endocrine therapy.

  2010cites this paper
• Tissue factor and thrombosis: The clot starts here

  2010cites this paper
• Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.

  2009cites this paper
• Emerging Links Between Thrombosis, Inflammation, and Angiogenesis: Key Role of Heparin and Low-Molecular-Weight Heparins

  2009cites this paper
• A Case of Warfarin-Associated Venous Limb Gangrene: Implications of Anticoagulation in a Palliative Care Setting

  2009cites this paper
• Tissue factor and cancer stem cells: is there a linkage?

  2009cites this paper
• Management of venous thromboembolism in patients with cancer.

  2009cites this paper
• Antithrombotic therapy in palliative care

  2009cites this paper
• Does antithrombotic therapy improve survival in cancer patients?

  2009cites this paper
• Tissue Factor Pathway Inhibitor [Tfpi]: A Natural Coagulation Inhibitor and Potential Therapeutic Agent – A Review

  2009cites this paper